ProstaLund
0,368 SEK +2,22%Vær den første som følger denne virksomhed
ProstaLund operates in medical technology. Today, specialisation is mainly in the area of treatment of benign prostate enlargement (BPH). Through the company CoreTherm, heat treatment of benign prostate enlargement is offered, without the need for surgical operation. The vision is to offer both faster and more efficient solutions against traditional forms of infestation. The company was founded in 1991 and is operating globally, based in Lund.
Omsætning
22,21 mio.
EBIT %
-75,87 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
PLUN
Daglig lav / høj pris
0,203 / 0,368
SEK
Markedsværdi
45,28 mio. SEK
Aktieomsætning
27,63 t SEK
Volumen
78 t
Finanskalender
Delårsrapport
07.11.2024
Årsrapport
20.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Mats Alyhr | 22,4 % | 22,4 % |
| Försäkringsaktiebolaget, Avanza pension | 9,0 % | 9,0 % |
| BFCM P/C BFCM Sweden Retail LT | 5,5 % | 5,5 % |
| Ålandsbanken | 3,5 % | 3,5 % |
| Nordnet Pensionsförsäkring | 2,9 % | 2,9 % |
| Fenja Capital i A/S | 2,7 % | 2,7 % |
| SEB Life International | 2,3 % | 2,3 % |
| Oskar Alyhr | 1,6 % | 1,6 % |
| Capmate Aktiebolag | 1,6 % | 1,6 % |
| Nilsson, Arve | 1,3 % | 1,3 % |
ViserAlle indholdstyper
Published study confirming effectiveness of transurethral intraprostatic anaesthesia (TUIA) using our Schelin Catheter®
First patients treated with CoreTherm® Concept in Austria
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools